uploads/2018/04/Modern-Insulin-1.png

A Review of Novo Nordisk’s Modern Insulin

By

Updated

Modern insulin revenue trends

Novo Nordisk’s (NVO) modern insulins include NovoRapid, Levemir, and NovoMix. In 4Q17, its modern insulins generated revenues of 10.4 billion Danish kroner, which is a ~9% YoY (year-over-year) decline in local currency.

In fiscal 2017, its modern insulins reported revenues of 44 billion Danish kroner, which reflected a ~4% YoY decline in local currency.

Lower sales of Levemir in North America (the United States and Canada) primarily attributed to the decline of net revenues of Novo Nordisk’s modern insulins. The launch of Tresiba and its rapid uptake also negatively impacted sales of modern insulins.

Article continues below advertisement

NovoRapid revenue trends

In 4Q17, NovoRapid generated revenues of 4.6 billion Danish kroner, which was an ~11% YoY decline in local currency.

In fiscal 2017, NovoRapid generated revenues of 20 billion Danish kroner, which is a ~3% YoY growth in local currency.

In 2017 in the United States and Europe, NovoRapid generated revenues of 10.6 billion Danish kroner and 4.3 billion Danish kroner, respectively. That was a ~2% YoY decline and a ~3% YoY growth, respectively, in local currency.

In 2017, in AAMEO (Asia, Africa, the Middle East, and Oceania), China, Japan and Korea, and Latin America, NovoRapid generated revenues of 2.3 billion Danish kroner, 1.3 billion Danish kroner, 941 million Danish kroner, and 335 million Danish kroner, respectively. That’s a ~19% YoY growth, a ~23% YoY growth, a ~1% YoY decline, and a ~40% YoY growth, respectively, in local currencies.

Article continues below advertisement

Levemir revenue trends

In 4Q17, Levemir generated revenues of 3.3 billion Danish kroner, which is an ~11% YoY decline in local currency.

In 2017, Levemir reported revenues of 14 billion Danish kroner, which reflected a ~15% YoY decline in local currency.

In 2017 in the United States and Europe, Levemir reported revenues of 9.3 billion Danish kroner and 2.4 billion Danish kroner, respectively, which reflected a ~22% and ~4% YoY decline, respectively.

NovoMix revenue trends

In 4Q17, NovoMix generated revenues of 2.5 billion Danish kroner, which is a ~1% YoY growth in local currency.

In 2017, NovoMix generated revenues of 10.3 billion Danish kroner, which reflected a ~1% YoY growth. In 2017, in the United States, Europe, AAMEO, China, Japan and Korea, and Latin America, NovoMix reported revenues of 1.7 billion Danish kroner, 1.9 billion Danish kroner, 2.5 billion Danish kroner, 3.5 billion Danish kroner, 444 million Danish kroner, and 113 million Danish kroner, respectively. That’s a ~3% decline, a ~7% decline, a ~14% growth, a ~9% growth, a ~26% decline, and a ~24% growth, respectively, on a YoY basis in local currency.

In the marketplace, Novo Nordisk’s modern insulin portfolio competes with Sanofi’s (SNY) Apidra and Eli Lilly’s (LLY) Humalog and Humulin.

Advertisement

More From Market Realist